Lakpura LLC – FDA Warning Letter, Oct 17, 2022
On October 24, 2022, the FDA and FTC issued a Warning Letter to Lakpura.com following website reviews on September 26 and October 17, 2022. The agencies found that Lakpura.com offers products like “Beam Suwa Dharani” and “Siddhalepa Lakpeyawa” for sale in the U.S., claiming they mitigate, prevent, treat, diagnose, or cure COVID-19.
These products are deemed unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). Their introduction into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)). The letter emphasizes the ongoing public health emergency due to COVID-19.
Lakpura.com must immediately cease selling all unapproved and unauthorized COVID-19 related products. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov detailing corrective actions, including steps to prevent recurrence and supporting documentation. Failure to comply may lead to legal action, including seizure and injunction. The firm will be
ID · 1fefc5d6-41d6-4f2d-a3b2-57f373f91eec
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.